QQQ   265.39 (+0.47%)
AAPL   108.22 (+1.03%)
MSFT   203.19 (+1.30%)
FB   249.53 (+0.20%)
GOOGL   1,422.86 (+0.96%)
AMZN   3,019.79 (+0.66%)
NVDA   493.92 (+1.85%)
TSLA   387.79 (+1.95%)
BABA   269.73 (-1.18%)
CGC   14.27 (-2.26%)
GE   6.06 (-0.82%)
MU   49.47 (-0.76%)
AMD   75.82 (+1.46%)
T   28.04 (+0.61%)
F   6.66 (+0.30%)
ACB   5.20 (+0.58%)
GILD   62.25 (-1.33%)
NFLX   473.08 (+0.52%)
DIS   122.49 (-0.64%)
BAC   23.34 (+0.34%)
BA   146.05 (-3.39%)
QQQ   265.39 (+0.47%)
AAPL   108.22 (+1.03%)
MSFT   203.19 (+1.30%)
FB   249.53 (+0.20%)
GOOGL   1,422.86 (+0.96%)
AMZN   3,019.79 (+0.66%)
NVDA   493.92 (+1.85%)
TSLA   387.79 (+1.95%)
BABA   269.73 (-1.18%)
CGC   14.27 (-2.26%)
GE   6.06 (-0.82%)
MU   49.47 (-0.76%)
AMD   75.82 (+1.46%)
T   28.04 (+0.61%)
F   6.66 (+0.30%)
ACB   5.20 (+0.58%)
GILD   62.25 (-1.33%)
NFLX   473.08 (+0.52%)
DIS   122.49 (-0.64%)
BAC   23.34 (+0.34%)
BA   146.05 (-3.39%)
QQQ   265.39 (+0.47%)
AAPL   108.22 (+1.03%)
MSFT   203.19 (+1.30%)
FB   249.53 (+0.20%)
GOOGL   1,422.86 (+0.96%)
AMZN   3,019.79 (+0.66%)
NVDA   493.92 (+1.85%)
TSLA   387.79 (+1.95%)
BABA   269.73 (-1.18%)
CGC   14.27 (-2.26%)
GE   6.06 (-0.82%)
MU   49.47 (-0.76%)
AMD   75.82 (+1.46%)
T   28.04 (+0.61%)
F   6.66 (+0.30%)
ACB   5.20 (+0.58%)
GILD   62.25 (-1.33%)
NFLX   473.08 (+0.52%)
DIS   122.49 (-0.64%)
BAC   23.34 (+0.34%)
BA   146.05 (-3.39%)
QQQ   265.39 (+0.47%)
AAPL   108.22 (+1.03%)
MSFT   203.19 (+1.30%)
FB   249.53 (+0.20%)
GOOGL   1,422.86 (+0.96%)
AMZN   3,019.79 (+0.66%)
NVDA   493.92 (+1.85%)
TSLA   387.79 (+1.95%)
BABA   269.73 (-1.18%)
CGC   14.27 (-2.26%)
GE   6.06 (-0.82%)
MU   49.47 (-0.76%)
AMD   75.82 (+1.46%)
T   28.04 (+0.61%)
F   6.66 (+0.30%)
ACB   5.20 (+0.58%)
GILD   62.25 (-1.33%)
NFLX   473.08 (+0.52%)
DIS   122.49 (-0.64%)
BAC   23.34 (+0.34%)
BA   146.05 (-3.39%)
Log in
NASDAQ:MNOV

MediciNova Stock Forecast, Price & News

$4.67
-1.32 (-22.04 %)
(As of 09/24/2020 12:00 AM ET)
Add
Compare
Today's Range
$4.63
Now: $4.67
$5.48
50-Day Range
$5.05
MA: $5.65
$6.39
52-Week Range
$2.79
Now: $4.67
$13.25
Volume1.76 million shs
Average Volume764,935 shs
Market Capitalization$207.22 million
P/E RatioN/A
Dividend YieldN/A
Beta1.52
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective ß2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.
Read More
MediciNova logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.24 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MNOV
CUSIPN/A
Phone858-373-1500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.71 per share

Profitability

Net Income$-12,940,000.00

Miscellaneous

Employees9
Market Cap$207.22 million
Next Earnings Date10/23/2020 (Estimated)
OptionableOptionable
$4.67
-1.32 (-22.04 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MNOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











MediciNova (NASDAQ:MNOV) Frequently Asked Questions

How has MediciNova's stock been impacted by COVID-19?

MediciNova's stock was trading at $3.29 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MNOV stock has increased by 41.9% and is now trading at $4.67.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of MediciNova?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for MediciNova
.

When is MediciNova's next earnings date?

MediciNova is scheduled to release its next quarterly earnings announcement on Friday, October 23rd 2020.
View our earnings forecast for MediciNova
.

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) posted its quarterly earnings data on Tuesday, July, 28th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.02.
View MediciNova's earnings history
.

What price target have analysts set for MNOV?

1 equities research analysts have issued 1 year price objectives for MediciNova's stock. Their forecasts range from $11.00 to $11.00. On average, they expect MediciNova's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 135.5% from the stock's current price.
View analysts' price targets for MediciNova
.

Are investors shorting MediciNova?

MediciNova saw a decline in short interest during the month of August. As of August 14th, there was short interest totaling 2,350,000 shares, a decline of 19.2% from the July 30th total of 2,910,000 shares. Based on an average daily trading volume, of 1,620,000 shares, the days-to-cover ratio is currently 1.5 days. Currently, 6.3% of the shares of the stock are sold short.
View MediciNova's Short Interest
.

Who are some of MediciNova's key competitors?

What other stocks do shareholders of MediciNova own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediciNova investors own include Iovance Biotherapeutics (IOVA), Novavax (NVAX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), Opko Health (OPK), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), MEI Pharma (MEIP), VIVUS (VVUS) and Aldeyra Therapeutics (ALDX).

Who are MediciNova's key executives?

MediciNova's management team includes the following people:
  • Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 69)
  • Mr. Masatsune Okajima, Head of Japanese Office & VP (Age 51)
  • Dr. Kazuko Matsuda M.P.H., M.D., Ph.D., MPH, Chief Medical Officer (Age 53)
  • Ms. Carla Reyes, Chief Financial Officer (Age 47)
  • Mr. John O'Neil CPA, Controller

What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

Who are MediciNova's major shareholders?

MediciNova's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (0.42%), Nuveen Asset Management LLC (0.41%), Charles Schwab Investment Management Inc. (0.23%), California Public Employees Retirement System (0.19%), Alps Advisors Inc. (0.14%) and Bank of America Corp DE (0.07%). Company insiders that own MediciNova stock include Hideki Nagao, Kazuko Matsuda and Yuichi Iwaki.
View institutional ownership trends for MediciNova
.

Which institutional investors are selling MediciNova stock?

MNOV stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc., UBS Group AG, and Goldman Sachs Group Inc..
View insider buying and selling activity for MediciNova
.

Which institutional investors are buying MediciNova stock?

MNOV stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Bank of New York Mellon Corp, State of Wisconsin Investment Board, SG Americas Securities LLC, California Public Employees Retirement System, Charles Schwab Investment Management Inc., State Board of Administration of Florida Retirement System, and Bank of America Corp DE. Company insiders that have bought MediciNova stock in the last two years include Kazuko Matsuda, and Yuichi Iwaki.
View insider buying and selling activity for MediciNova
.

How do I buy shares of MediciNova?

Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MediciNova's stock price today?

One share of MNOV stock can currently be purchased for approximately $4.67.

How big of a company is MediciNova?

MediciNova has a market capitalization of $207.22 million. MediciNova employs 9 workers across the globe.

What is MediciNova's official website?

The official website for MediciNova is medicinova.com.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]

This page was last updated on 9/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.